Martin Faehling
A5021115529- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Pulmonary Hypertension Research and Treatments
- Peptidase Inhibition and Analysis
- Pleural and Pulmonary Diseases
- Venous Thromboembolism Diagnosis and Management
- Medical Imaging and Pathology Studies
- Neuroendocrine Tumor Research Advances
- Pancreatic function and diabetes
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Corporate Governance and Law
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Adenosine and Purinergic Signaling
- Tuberous Sclerosis Complex Research
- Medical Imaging Techniques and Applications
- Congenital Diaphragmatic Hernia Studies
- Multiple and Secondary Primary Cancers
- Atrial Fibrillation Management and Outcomes
- Gastric Cancer Management and Outcomes
- Occupational and environmental lung diseases
Klinikum Esslingen
2016-2025
Fischer (Germany)
2023
Iomedico (Germany)
2023
National Center for Tumor Diseases
2021
Kliniken der Stadt Köln
2006
Universität Ulm
2001-2002
University of Oxford
1998
Brain Physiology Lab
1997
Abstract Aims To systematically assess late outcomes of acute pulmonary embolism (PE) and to investigate the clinical implications post-PE impairment (PPEI) fulfilling prospectively defined criteria. Methods results A prospective multicentre observational cohort study was conducted in 17 large-volume centres across Germany. Adult consecutive patients with confirmed symptomatic PE were followed a standardized assessment plan pre-defined visits at 3, 12, 24 months. The co-primary (i) diagnosis...
The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti-PD-(L)1, and targeted treatment for actionable genomic alterations (AGAs). Primary analysis is reported.
BackgroundAfatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade afatinib plus paclitaxel superior outcomes versus switching to chemotherapy alone acquiring resistance erlotinib/gefitinib and monotherapy.Patients methodsPatients relapsed/refractory disease following ≥1 line of chemotherapy, whose tumors had progressed...
Tyrosine kinase inhibitors currently confer the greatest survival gain for nonsmall cell lung cancer (NSCLC) patients with actionable genetic alterations. Simultaneously, increasing number of targets and compounds poses challenge reliable, broad timely molecular assays identification likely to benefit from novel treatments. Here, we demonstrate feasibility clinical utility comprehensive, NGS‐based profiling routine workup advanced NSCLC based on first 3,000 analyzed in our department....
BackgroundThe efficacy of checkpoint inhibitors for non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METΔ14ex) remains controversial.Materials and methods110 consecutive METΔ14ex NSCLC patients receiving first-line chemotherapy (CHT) and/or immunotherapy (IO) in 10 German centers between 2016-2022 were analyzed.ResultsCombined CHT-IO was given to 35/110 (32%) patients, IO alone 43/110 (39%), CHT 32/110 (29%) upfront. Compared CHT, showed longer progression-free survival (median...
<h3>Background</h3> Few data are available on the long-term course and predictors of quality life (QoL) following acute pulmonary embolism (PE). <h3>Research Question</h3> What kinetics determinants disease-specific generic health-related QoL 3 12 months an PE? <h3>Study Design Methods</h3> The Follow-up after Acute Pulmonary Embolism (FOCUS) study prospectively followed up consecutive adult patients with objectively diagnosed PE. Patients were considered for who completed Quality Life...
PD-(L)1 inhibitors have improved prognosis of non-small-cell lung cancer (NSCLC), but can also cause immune-related adverse events (irAEs) that complicate management.We analyzed NSCLC patients receiving from 2012 to 2020 in a German academic center.IrAE showed comparable frequencies stage IV (198/894 or 22%) vs. III (14/45 31%, p = 0.15), after anti-PD-(L)1 monotherapy chemoimmunotherapy (139/483 58/213, 0.75), and across treatment lines. In IV, irAE occurred 3.1 months median, affected...
We report on the results of German early access program (EAP) with third-generation ALK- and ROS1-inhibitor lorlatinib.Patients documented treatment failure all approved ALK/ROS1-specific therapies or resistance mutations not covered by inhibitors leptomeningeal carcinomatosis were enrolled analyzed.In total, 52 patients included [median age 57 years (range 32-81), 54% female, 62% never smokers, 98% adenocarcinoma]; 71% 29% ROS1-positive, respectively. G1202R G2032R prior to lorlatinib...
Vascular endothelial growth factor-A (VEGF-A) plays a major role in tumor angiogenesis and raises the concentration of intracellular free calcium ([Ca2+]i). Carboxyamidotriazole (CAI), an inhibitor influx angiogenesis, is under investigation as tumoristatic agent. We studied effect CAI [Ca2+]i VEGF-A signaling human cells. induced biphasic signal. increased level inositol 1,4,5-trisphosphate (IP3), which suggests that releases Ca2+ from IP3-sensitive stores induces store-operated influx....
Introduction: Pulmonary hypertension (PH) is a common complication in patients with congenital heart disease (CHD), aggravating the natural, post-operative, or post-interventional course of underlying anomaly. The various CHDs differ substantially characteristics, functionality, and clinical outcomes among each other compared diseases pulmonary hypertension. Objective: To describe current management strategies for adults PH relation to different types CHD based on real-world data. Methods...
Epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer (NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted therapies, but implementation is challenging.EGFR+ NSCLC treated with first/second-generation (1G/2G) TKI at our institution a last follow-up after osimertinib approval (February 2016), were analyzed retrospectively, and the results compared published data under osimertinib.A total of 207 received erlotinib (37%), gefitinib...
Abstract Aims Patients surviving acute pulmonary embolism (PE) necessitate long-term treatment and follow-up. We estimated, the chronic economic impact of PE on German healthcare system. Methods results calculated direct cost illness during first year after discharge for index PE, analysing data from a multicentre prospective cohort study in Germany. Main accompanying readmission diagnoses were used to calculate DRG-based hospital reimbursements; anticoagulation costs estimated exact...
Treatment of lung adenocarcinoma has changed and now includes checkpoint inhibitors (CPIs) or, in the case an EGFR mutation, third-generation TKI osimertinib. Few data compare long-term overall survival (OS) current historic subgroups. This real-world analysis (KOMPASS study) included stage IV lung-adenocarcinoma patients with either EGFR, KRAS, or no mutation. Patients were assigned to "current" no-mutation cohort if they had mutation testing using NGS (n = 199; median date diagnosis 2021)....
8512 Background: At the second interim analysis (IA2) of triple-blind, phase 3 PEARLS/KEYNOTE-091 study (NCT02504372), pembrolizumab significantly improved DFS compared with placebo in patients (pts) completely resected stage IB (T ≥4 cm) to IIIA NSCLC per AJCC v7, regardless PD-L1 expression (N = 1177, HR 0.76, 95% CI 0.63-0.91, P 0.0014). We present subgroups related surgery, disease burden, and adjuvant chemotherapy use. Methods: Pts had pathologically confirmed, any ECOG PS 0-1....
<i>Background:</i> Erlotinib is a standard of treatment for metastatic non-small-cell lung cancer after failure initial therapy. Patient selection based on clinical factors under discussion. <i>Methods:</i> We analyzed the outcome in relation to 121 consecutive Caucasian patients treated with erlotinib routine setting comprehensive center and 2 regional oncology centers. <i>Results:</i> For at 1st/2nd/3rd/≧4th line, progression-free survival (PFS) was...